

TABLE 1 Patient Characteristics

Patient ID	Gender#	Age	Tissue Involvement	Enrollment Criteria	Time from Initial Diagnosis to CAR-T infusion, months	Genetic variation	MRD before CART	Infusion Dose (*10^6/kg)
S001	M	4.3	BM, subcutaneous tumor	Relapse	7.50	TCF3-PBX1	95.83%	6.9
S002	F	7.2	BM and CNS	2nd Relapse	44.07	-	0.27%	10
S003	F	6.1	BM and CNS	2nd Relapse after HSCT	50.10	ETV6-RUNX1	31.35%	12
S004	F	8.7	BM and CNS	2nd Relapse	72.87	ZCCHC7-CSF2RA	2.41%	15
S005	M	9.3	BM and testis	Relapse	40.10	ETV6-RUNX1	1.00%	15
S006	F	7.4	BM, subcutaneous tumor	Relapse	44.17	ND	0.46%	10
S007	M	7.1	BM, CNS and testis	2nd Relapse	48.27	-	3.00%	8.8
S008	F	13	BM and CNS	2nd Relapse	116.83	ETV6: exon2 del	32.40%	1.8

#M=male; F=female.